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30. THE LPS STIMULATED PRODUCTION OF INTERLEUKIN-
10 IS NOT ASSOCIATED WITH -819C/T AND -592C/A
PROMOTER POLYMORPHISMS IN HEALTHY
INDIAN SUBJECTS
Skanda Shukla, Able Lawrence, Amita Aggarwal and Sita Naik
Immunology, SGPGIMS, Lucknow, India
Background: Interleukin-10 is a pivotal immunoregulatory cytokine
with pleiotropic effects on the immune system. IL-10 promoter
polymorphisms have been associated with disease susceptibility and
the ability to secrete IL-10 in vitro. We suspected that the association
of the widely studied -819C/T and -592C/A polymorphisms with the
IL-10 production might vary between ethnic groups. Therefore, we
examined the association of -819 C/T and -592 C/A promoter
polymorphisms with in vitro LPS stimulated secretion of IL-10 in
normal healthy Indian volunteers.
Methods: Peripheral blood was collected from 103 healthy volunteers
and diluted whole blood cultures were set up with 100 ng/ml of LPS as
stimulant: supernatant was collected at 24 h and IL-10 levels were
assayed by ELISA. Genotyping was done for -819C/T polymorphism in
101 individuals and -592C/A polymorphism in 68 individuals
by polymerase chain reaction followed by RFLP. The differences
in IL-10 production between the genotypes were analysed by
ANOVA.
Results: There were 30, 47 and 24 individuals with the CC, CT and TT
genotypes with a minor allele (T) frequency of 47% for the -819C/T
polymorphism. The CC and TT genotypes at position -819 were
strongly associated with CC and AA genotypes at -592 position
suggestive of strong linkage disequilibrium. There was no association
between the -819 genotype and the in vitro LPS stimulated IL-10
levels.
Conclusions: The -819C/T and the -592 C/A polymorphisms of the IL-
10 promoter region are not significantly associated with LPS
stimulated IL-10 production healthy Indian subjects.
Disclosure statement: All authors have declared no conflicts of
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31. IL-17 PRODUCING CELLS ARE INCREASED IN THE
PERIPHERAL BLOOD OF PATIENTS WITH RA AND ARE
ENRICHED AT THE SITE OF INFLAMMATION
Nicola J. Gullick1,2, Hayley G. Evans1,2, David Jayaraj1,2, Bruce
W. Kirkham2,3 and Leonie S. Taams1,2
1CMCBI, King’s College, London, UK; 2NIHR Comprehensive
Biomedical Research Centre, Guy’s and St Thomas’ NHS Foundation
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Background: Th17 cells are a recently identified CD4þ T cell subset
characterized by production of Interleukin-17A (IL-17). IL-17 is a highly
pro-inflammatory cytokine with effects on multiple cells and tissues
and Th17 cells are likely to have an important role in the pathogenesis
of a number of immune-mediated diseases including rheumatoid
arthritis (RA). IL-17 recruits other immune cells, induces inflammatory
cytokines and is involved in osteoclastogenesis and development of
bone erosions. The aim of this study was to identify if Th17 cells are
increased in peripheral blood from patients with RA and if these cells
are increased at the site of inflammation.
Methods: Peripheral blood mononuclear cells (PBMC) were isolated
from healthy controls or patients with RA and stimulated with
PMA and ionomycin for 3 h in the presence of golgistop. Paired
synovial fluid (SF) from inflamed knee joints was analysed where
available. Synovial tissue was available for five RA patients from
arthroscopic biopsies (knee/elbow). Synovial tissue was digested with
collagenase prior to stimulation. Intracellular expression of IL-17,
Interferon- (IFN) and TNFa was determined by multicolour flow
cytometry.
Comparisons between patients and healthy controls were made
using student t-tests for normally distributed data or Mann-Whitney U
tests for non-normal data. Paired data (PB vs. SF) were analysed
using paired t tests or Wilcoxon signed rank tests using GraphPad
Prism.
Results: Peripheral blood samples were collected from 29 patients
with established RA and 23 healthy controls. Th17 cells were present
at increased levels in PBMC from RA patients with median (IQR) of
0.56% (1.36) vs. 0.32% (0.36) in healthy controls (P¼0.03). A small
percentage of cells positive for both IL-17 and IFN were observed,
which was higher in RA patients.
Paired PB and SF samples were analysed for 14 patients
(16 knees). Cytokine producing cells were generally elevated in SF
(TNFa, IL-17 or IFN-producing CD4þ T cells and TNFa or IL-1b
producing CD68þ monocytes). The percentage of total IL-17
producing CD4þ T cells was significantly elevated within SF vs. PB,
particularly those with a dual Th17/Th1 phenotype rather than a
specific increase in Th17 cells. IL-17 producing T cells were present in
synovial tissue (n¼5); with three of five patients showing very high
levels (>8%). Interestingly, the two patients with low levels (<1%)
were clinically in remission with DAS28 <2.6.
Conclusions: Th17 cells are increased in PB from patients with RA
relative to healthy donors. Furthermore, we demonstrate an increased
percentage of IL-17 producing cells in RA SF, with a shift towards a
Th1/Th17 phenotype. Th17 cells are not always increased in ST and
higher levels of IL-17þ cells may indicate more active disease. We are
now investigating relationships with other measures of disease activity
including inflammatory markers and imaging such as power Doppler
ultrasound.
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32. BIOMARKER PROFILES ASSOCIATED WITH DISEASE
FEATURES IN PATIENTS WITH EARLY RA
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Background: The inflammatory process in RA is associated with
excess production of many inflammatory mediators including cyto-
kines and matrix metalloproteinases (MMPs). Numerous studies have
shown that individual biomarkers are associated with particular clinical
measures of RA. However, the inflammatory process involves a
complex network of pro- and anti-inflammatory mediators, so
identifying combinations of biomarkers associated with disease
features may lead to a better understanding of the molecular pathways
involved. The aim of this study was to determine whether disease
measures in patients with early RA and at 5-year follow up are
associated with particular baseline profiles of circulating cytokines and
MMPs.
Methods: Seventy-four DMARD naı¨ve RA patients with a disease
duration of <1 year were investigated. Baseline serum samples were
collected and assayed for protein levels of 30 different molecules using
bead-based multiplex assays (Luminex) and ELISAs. Principal com-
ponent analysis (PCA) was used to reduce the number of biomarkers
to a smaller set of independent components, which were investigated
for their association with disease measures by using regression
techniques.
Results: PCA identified 7 components consisting of various combina-
tions of cytokines and MMPs. The strongest association with
measures of disease activity and pain was found with a component
consisting of MMP-1, MMP-3, PDGF, VEGF and osteopontin (OPN)
(see Table). Another component consisting of MIP-1a, IL-9, IL-13 was
also associated with markers of inflammation, pain, rheumatoid factor
and joint damage. A history of smoking was strongly associated with a
profile which included MMP-9, MMP-8, IL-8, OPN and osteoprotegerin
(OPG). The MMP-1, MMP-3, VEGF, PDGF and OPN component and
MIP-1a, IL-9 and IL-13 component were predictive of worse function
and damage scores at 5-year follow up.
Conclusions: Our results indicate that different features of the disease
are associated with different cytokine/MMP profiles. Our data confirm
the importance of molecules involved in angiogenesis and matrix
remodelling in the early stages of the disease.
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Variable MMP-9, MMP-8,
OPG, IL-8, OPN
VEGF, MMP-3,
MMP-1, OPN, PDGF
MIP-1a, IL-9,
IL-13
Baseline
CRP < 0.0001 0.07
VAS 0.005 0.02
DAS44CRP 0.02 0.07
Stoke index 0.0005 0.0046
HAQ 0.01 0.03
OSRA-A < 0.0001 0.01
OSRA-D 0.01
Smoked (þ/-) 0.001
5 year
CRP 0.0079
OSRA-D 0.0001 0.001
RF (þ/-) 0.035
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33. MAPPING THE CYTOKINE NETWORK: SIMULTANEOUS
ANALYSIS OF CYTOKINE MRNA EXPRESSION PROFILES OF
FIVE IMMUNE CELL POPULATIONS ISOLATED FROM
SYNOVIAL FLUID AND PERIPHERAL BLOOD OF RA PATIENTS
Lorraine Yeo, Caroline Schmutz, Kai-Michael Toellner, Mike Salmon,
Andrew D. Filer, Christopher Buckley, Karim Raza and
Dagmar Scheel-Toellner
Rheumatology Research Group, University of Birmingham,
Birmingham, UK
Background: Cytokines act as part of a complex network of cells and
soluble factors to regulate the processes involved in chronic
inflammation and tissue destruction in rheumatoid arthritis. It is
important to try to understand the roles of cytokines as components
of larger networks rather than isolated pathways. As an initial step
towards the characterization of this network, we developed a method
that allows simultaneous analysis of cytokine mRNA expression by the
five largest cell populations present within the synovial fluid and
peripheral blood of rheumatoid arthritis patients. The cells are not
cultured or stimulated ex-vivo to reflect their in-vivo cytokine profile as
closely as possible.
Methods: Synovial fluid and peripheral blood were obtained from five
patients with early or established RA and cells were sorted into
five populations. CD3/CD4/CD45ROþ T cells, CD3/CD8/CD45ROþ
T cells, CD19þ B cells and CD14þ macrophages were sorted with a
Mo-FloTM high-speed cell sorter and neutrophils were isolated using
magnetic anti-CD15 beads on a MACSTM column. Purity of sorted cell
populations was assessed after each sort and samples of less than
95% purity were rejected. mRNA expression of 41 cytokines was
quantified by real-time PCR with the help of low-density array
microfluidic cards. In a series of validation experiments, we confirmed
that sample preparation and staining conditions were not affecting the
result and that cell numbers were sufficient for analysis.
Results: We have identified patterns of cytokine expression in
cytokines expressed by specific cell types or by a range of cell
types and have been able to make comparisons between cytokines
levels in cell populations in the synovial fluid with those in peripheral
blood. T cell cytokines IFN- and IL-2 were found only in T cell
populations, while cytokines characteristic for myeloid cells such as IL-
18 and CCL3 were only found in neutrophils and macrophages;
suggesting that we are indeed able to separate the cytokine profiles of
the main immune cell populations invading the rheumatoid synovial
fluid.
Conclusions: Complex patterns of cytokine production have been
identified and are now allowing us to map which cytokines are
expressed in the individual immune cell populations of the synovial
fluid and peripheral blood of RA patients.
Disclosure statement: All authors have declared no conflicts of
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34. BLOOD LIPID LEVELS ARE LOWERED BY INCREASED
INTERLEUKIN-6 CONCENTRATIONS VIA UP-REGULATION OF
THE VERY LOW DENSITY LIPOPROTEIN RECEPTOR
M. Hashizume, H. Yoshida, N. Koike, M. Suzuki and M. Mihara
Product Research Department, Chugai Pharmaceutical Co. Ltd,
Gotemba, Japan
Background: In patients with rheumatoid arthritis (RA), blockade of
interleukin-6 (IL-6) or tumour necrosis factor-a (TNF-a) can increase
blood concentrations of total cholesterol, high-density lipoprotein
(HDL) cholesterol and triglycerides. These changes are inversely
correlated to RA disease activity, but the mechanisms by which lipids
are increased are unclear. The low-density lipoprotein receptor (LDLR)
family, which includes LDLR, LDL receptor-related protein-1 (LRP-1)
and very low-density lipoprotein receptor (VLDLR), is involved in lipid
uptake and control of blood lipid levels. To investigate the mechanisms
of lipid changes induced by blockade of IL-6 and TNF-a, we have
investigated the effects of IL-6 and TNF-a on the expression of these
scavenger lipid receptors.
Methods: In vitro, vascular skeletal muscle cells (VSMC) were cultured
in the presence of IL-6 alone, soluble IL-6 receptor (sIL-6R), IL-6 plus
sIL-6R, or TNF-a alone for 24 h. Expression of VLDLR, LDLR and
LRP-1 were measured by real-time polymerase chain reaction. In vivo,
human IL-6 was injected into mice twice a day for 2 weeks and
changes in blood levels of total cholesterol and triglycerides and
expression of VLDLR in different tissues were measured. In addition,
the effects of anti-IL-6 receptor (IL-6R) antibody injection on blood lipid
levels in normal and IL-6-treated mice were investigated.
Results: The expression of VLDLR mRNA in VSMC in vitro was
significantly increased by IL-6 plus sIL-6R but not by IL-6, sIL-6R or
TNF-a alone. None of the treatments induced LDLR or LRP-1 mRNA
expression. In mice, IL-6 treatment significantly reduced blood levels
of total cholesterol and triglycerides, although there were no changes
in body weight or food intake. VLDLR mRNA expression was increased
in all tissues and organs of IL-6-treated mice compared with PBS-
treated controls. Administration of anti-IL-6R antibody to IL-6-treated
mice increased total cholesterol and triglyceride levels to those of
PBS-treated mice and reduced levels of the acute-phase protein
serum amyloid A. Administration of anti-IL-6R antibody to normal (non-
IL-6-treated) mice did not result in any changes to total cholesterol or
triglyceride levels.
Conclusions: Over-produced IL-6 decreased blood lipid levels by
increasing VLDLR expression in several tissues. As TNF-a blockers
reduce blood IL-6 levels, we conclude that IL-6 and TNF-a blockades
normalize reduced lipid levels caused by IL-6 but do not affect normal
lipid metabolism.
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35. EFFECTS OF ANTI-TUMOUR NECROSIS FACTOR a
THERAPY ON INSULIN KINETICS IN NORMAL-WEIGHT AND
OBESE PATIENTS WITH RHEUMATOID ARTHRITIS
Antonios Stavropoulos-Kalinoglou1,2, Giorgos S. Metsios1,3,
Karen M. Douglas1, Vasileios F. Panoulas1, Yiannis Koutedakis3 and
George D. Kitas1
1Rheumatology, Dudley Group of Hospitals, Dudley, UK; 2School of
Sports and Exercise Science, University of Birmingham, Birmingham,
UK; 3School of Sports, Performing Arts and Leisure, University of
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Background: Anti-tumour necrosis factor alpha (anti-TNFa) therapies
are commonly used in the treatment of rheumatoid arthritis (RA). Apart
from their anti-rheumatic effects, anti-TNFa drugs have been sug-
gested to reduce CVD risk and to improve insulin kinetics. In RA,
insulin resistance (IR) is common and it is a potential contributor to the
increased risk of cardiovascular disease (CVD) of these patients.
Obesity, a potent contributor to IR in the general population, might
influence the way anti-TNFa therapy affects insulin kinetics. The aim of
this longitudinal study was to compare the effects of anti-TNFa therapy
on insulin kinetics between normal weight and obese RA patients with
and without IR.
Methods: Normal-weight (Nþ IR) or obese patients with IR (Oþ IR)
embarking on anti-TNFa treatment were invited to participate. They
were assessed for body mass index (BMI), lipids, blood pressure,
glucose and insulin and RA disease characteristics, prior to and
following 6 months of anti-TNFa treatment. Their results were
compared with age, gender, BMI, disease duration and smoking
status matched normal-weight patients without IR (N-IR) and
obese without IR (N-IR). IR was defined as HOMA 2.5, QUICKI
0.333, presence of diabetes mellitus or use of anti-diabetic
medication.
Results: Twenty patients (five in each group) participated (age¼ 56.1
years S.D.¼6.2). All groups consisted of three females and two males.
None had diabetes mellitus or was using anti-diabetic medication.
Anti-TNFa treatment did not affect BMI in any of the groups (P>0.05).
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Repeated measures ANOVA indicated that inflammation (as indicated
by ESR, CRP and DAS) was equally reduced in all groups (P for
differences between groups >0.05 in all cases). However, HOMA
(p¼0.031) and QUICKI (P¼0.025) was reduced significantly more in
the Nþ IR group compared with the N-IR group. Similarly, anti-TNFa
treatment resulted in greater decreases in systolic BP (P¼ 0.048) and
triglycerides (P¼0.034) in these patients. On the other hand, it
marginally improved insulin sensitivity in both Oþ IR and O-IR
individuals; however no differences in the magnitude of improvements
between the two groups were observed (P>0.05 for both HOMA and
QUICKI). Similarly, lipids and blood pressure were marginally improved
in obese individuals but not to a significant extent. Finally, the
reduction of inflammation (as indicated by CRP) correlated with the
reduction in HOMA (r¼ 0.55, P¼ 0.000) and QUICKI (r¼0.49,
P¼0.000) only in the Nþ IR group.
Conclusions: Anti-TNFa therapy seems to improve insulin kinetics in
normal weight patients with IR but not in obese patients with IR despite
the reduction in inflammation. It seems that IR among normal-weight
patients with RA is highly dependent on inflammation while IR among
obese RA patients possibly depends less on RA-related inflammation
and more on obesity.
Disclosure statement: All authors have declared no conflicts of
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36. CYTOKINE PROFILE AND FREQUENCY OF
IL-17-PRODUCING CD4 T CELLS IN BLOOD, SYNOVIAL FLUID
AND SYNOVIUM OF PATIENTS WITH RHEUMATOID
ARTHRITIS
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Background: Th17 cells have recently been implicated in the
pathogenesis and persistence of rheumatoid arthritis (RA). The aim
of this study was to systematically analyse the phenotype, cytokine
profile and frequency of interleukin-17 (IL-17) producing CD4-positive
T cells in mononuclear cells isolated from peripheral blood, synovial
fluid and synovium of patients with RA and to correlate Th17 cell
frequencies with clinical measures of disease activity.
Methods: Flow cytometry was used to analyse the surface phenotype
and cytokine production of mononuclear cells isolated from peripheral
blood (PBMC) (n¼ 44), synovial fluid (SFMC) (n¼14) and synovium
(SVMC) (n¼10) of patients with RA and PBMC of matched healthy
donors (n¼13) following treatment with PMA and ionomycin.
Results: The median proportion of IL-17-producing CD4 T cells in
SFMC (1.51% [0.62 - 3.17]) was greater than in PBMC (0.60% [0.33–
1.65]) from the same RA patients and PBMC (0.88% [0.71–1.51]) from
healthy donors, but was not statistically significant. Conversely, a
lower median proportion of IL-17-producing CD4 T cells in cells
isolated from RA synovium (SVMC) (0.80% [0.48–1.04]) compared with
PBMC (1.07% [0.43 - 1.64]) from those individuals was observed.
The frequencies of IFN-producing CD4 T cells were significantly
higher in RA SFMC (77.75% [62.37 - 85.93]) than paired PBMC
(59.97% [31.07–78.27]). The majority of IL-17-producing CD4 T cells
coexpressed IFN. IL-17-producing CD4 T cells in RA PBMC and
SFMC had very little IL-22 coexpression. However, the frequency of IL-
22-producing CD4 T cells in the PBMC did show a positive correlation
with the frequency of IL-17-producing CD4 T cells (r¼0.5735,
P<0.0004). IL-22-producing CD4 T cells in SFMC had an inverse
correlation with the DAS28 (r¼0.6747, P¼ 0.008). IL-17-producing
CD4 T cells had very little coexpression of IL-23R. The percentage of
IL-17-producing CD4 T cells coexpressing TNF was significantly
increased in SFMC compared with PBMC.
Conclusions: We did not find an enrichment of IL-17-producing CD4 T
cells in either RA SFMC or SVMC compared with PBMC. IL-17-
producing CD4 T cells in SFMC produced more TNF than their PBMC
counterparts, but were not a significant source of IL-22 and did not
express IL-23R. Given the data that IL-17 plays a pathogenic role in
RA, further work is required to determine whether this cytokine is
produced by other cell types in the rheumatoid environment.
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37. OBESITY IS A MAJOR DETERMINANT OF CRP LEVELS IN
HEALTHY INDIVIDUALS
Maria Juarez1, James Kolasinski1, Jyothish Govindan2,
Annette Quilter3, Lyn Williamson1, David A. Collins1 and Elizabeth
J. Price1
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Background: C-reactive protein (CRP) is a sensitive marker of
systemic inflammation routinely used in the diagnosis and monitoring
of inflammatory conditions. Studies also show links between CRP and
the metabolic syndrome, cardiovascular disease (CVD) and obesity
where IL6 released from adipose tissue is thought to induce low grade
systemic inflammation. Thus a correlation between CRP and obesity
would have significant implications in the clinical use and interpretation
of CRP. In a previous study, we demonstrated correlation between
CRP and body mass index (BMI) in RA patients. In this study, we
investigated the correlation between CRP and BMI in healthy
individuals.
Methods: Cross-sectional observational study. After obtaining RþD
and ethical approval, all hospital employees were invited to participate.
Subjects underwent physical examination, fasting blood testing and
completed a lifestyle questionnaire. High sensitivity CRP assay was
used. Lower detection limit was < 0.2 mg/l (normal range <6 mg/l).
127 participants had CRP levels lower than this and were assigned the
value of 0.1 mg/l. As distribution was highly skewed, statistical analysis
was performed using non parametric methods on rank values. BMI
groups were defined according to the World Health Organization
criteria: normal BMI 24.9 kg/m2, overweight BMI 25.0–29.9 kg/m2,
obese BMI 30 kg/m2.
Results: 365 participants (mean age 44.4 years, 82.7% female)
completed the study. 8 participants were excluded from analysis due
to intercurrent infection. There was a statistically significant associa-
tion between CRP and BMI. Normal BMI: median CRP 0.15 (IQR:
0.1–1.53 mg/l), overweight BMI: median CRP 1.3 (IQR: 0.1–2.8 mg/l),
obese BMI: median CRP 3.7 (IQR: 1.85–10.4 mg/l) (P< 0.0001). The
proportion of participants with CRP levels above the normal range
(>6 mg/l) increased with increasing BMI (P< 0.0001). A substantial
proportion of obese subjects (40%) had CRP values > 6 mg/l. Only
2 subjects in the obese group had a CRP value of < 0.2 mg/l. There
was a significant unadjusted correlation between CRP and BMI,
systolic and diastolic blood pressure, HDL, triglycerides, exercise and
smoking. The strongest correlation was observed between CRP and
BMI (r¼ 0.44). In the adjusted model BMI and triglycerides remained
significantly and independently related to CRP. BMI accounted for
19% of the variability in CRP, triglycerides for 2.6% and age and
gender for <1%.
Conclusions: CRP values increase with increasing BMI in normal
weight, overweight and obese individuals independently of other
confounding factors. This is particularly important given that 25% of
UK adults are obese. In the diagnosis and monitoring of inflammatory
disease CRP should be interpreted in the context of a subjects’ BMI,
as raised CRP levels may reflect body habitus rather than systemic
inflammation.
Disclosure statement: All authors have declared no conflicts of
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38. DETERMINANTS OF MEAN PLATELET VOLUME IN
PATIENTS WITH RHEUMATOID ARTHRITIS
Armen Y. Gasparyan, Antonios Stavropoulos-Kalinoglou, Tracey
E. Toms, Karen Douglas and George D. Kitas
Department of Rheumatology, Clinical Research Unit, Russell’s Hall
Hospital, Dudley Group of Hospitals NHS Foundation Trust, Dudley,
UK
Background: Rheumatoid arthritis (RA) is associated with increased
cardiovascular morbidity and mortality. A variety of classic and novel
cardiovascular risk factors are believed to enhance atherothrombosis
in RA. Mean platelet volume (MPV) is a valuable marker of a
prothrombotic state and high MPV values predict cardiovascular
events in the general population. The role of MPV and determinants of
its shifts have not been clarified in RA. We assessed MPV and its
determinants in RA.
Methods: 400 well-characterized consecutive RA patients were
enrolled. MPV was assessed by flow cytometry. Based on the
normal MPV range (7–10.7 fL), patients were divided into 2 groups:
those with low or normal MPV (<10.7 fL - lnMPV) and those with high
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MPV (10.7 fL - hMPV). The effect of demographic, anthropometric,
lifestyle (e.g. smoking) and RA-related (e.g. activity, severity, duration,
treatment) factors on MPV were assessed using univariate and binary
regression analyses.
Results: 316 patients (79%) were in the lnMPV group and 84 (21%) in
the hMPV group. Statistically significant differences were found
between lnMPV and hMPV in cigarette pack-years [mean (interquartile
range) 3 (0–20) and 0 (0–12); P¼0.04], systolic blood pressure [SBP
140 (125–151) vs. 144 (134–160); P¼0.008], diastolic blood pressure
(DBP 78.2 11.4 vs. 81.4410.4; P¼0.013) and platelet count [298
(254–373) vs. 277 (245–341); P¼0.024]. Binary regression analysis
showed that SBP and DBP were independent predictors of high MPV
(SBP - Odds Ratio 1.01, 95% CI 1.00–1.03; P¼ 0.011; DBP - 1.03,
1.00–1.05; P¼0.018), whereas cigarette pack-years and ESR were
independent predictors of low MPV [0.98 (0.96-1.0), P¼0.02 and 0.99
(0.98–1.0), P¼0.03, respectively).
Conclusions: Within the limitations of a cross-sectional study,
these results suggest that in RA, intensity of inflammation and
smoking independently associate with low(er) MPV, while the presence
of systolic or diastolic hypertension associate with high(er) MPV.
This and predictive value of MPV for future cardiovascular events
in RA need to be further investigated in prospective longitudinal
studies.
Disclosure statement: All authors have declared no conflicts of
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39. EFFICACY AND SAFETY OF CANAKINUMAB (ILARIS) IN A
LARGE COHORT OF PATIENTS ACROSS DIFFERENT
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Background: CAPS (disease spectrum consisting of FCAS, MWS,
NOMID) is a rare hereditary, autosomal dominant, systemic inflamma-
tory disease associated with excessive production of IL-1b. The fully
human monoclonal antibody canakinumab provides prolonged selec-
tive blockade of IL-1b.
Methods: Patients enrolled in this open-label multi-centre study
were canakinumab naı¨ve or rolled over from earlier phase II/III
studies. Patients received canakinumab 150 mg s.c. or 2 mg/kg s.c.
( 40 kg) every 8 weeks. The primary objective of this ongoing trial
is to assess the long-term safety and tolerability of canakinumab in
CAPS patients. Secondary objectives included assessment of
response (for naı¨ve patients), maintenance of response, percentage
of patients requiring dose adjustment and immunogenicity of
canakinumab. A relapse was defined as serum levels of CRP and/or
serum amyloid A protein (SAA) > 30 mg/l and physician’s global
assessment of disease activity >minimal or physician’s global
assessment of disease activity ¼minimal along with the assessment
of skin disease >minimal.
Results: Out of 98 patients (19 FCAS, 69 MWS, 9 MWS/NOMID,
1 cold urticaria/protocol deviation, 19 pediatric) aged 5–69 years
enrolled in the study, 44 patients were canakinumab-naı¨ve, while 54
had previously received canakinumab in another study. The median
duration of exposure to canakinumab was 113 days (range 9–232
days) and the mean number of injections per patient was 2.9 (range
1–9) at the time of this interim analysis. A complete response by Day 8
was seen in 41/44 (93.2%) canakinumab-naı¨ve patients. 13 patients
had missing relapse assessment data at the interim analysis cut off.
Of the remaining 85 patients, 77 had no relapse (90.6%), 5
experienced a relapse (5.9%) and 3 naı¨ve patients did not achieve
a complete response. At least one dose adjustment was required in
16 patients (16.3%). Adverse events (AEs) were predominantly mild to
moderate in severity, the most frequent AE was nasopharyngitis. Two
patients discontinued due to AEs (1 due to worsening of multiple
sclerosis like lesions and another due to MWS flare). Serious AEs
were reported in 5 patients and resolved while on treatment.
The majority of patients (94.9%) had no injection site reactions,
5.1% reported reactions, which were all mild. No anti-canakinumab
antibodies were observed.
Conclusions: For CAPS patients, canakinumab administered every
8 weeks, provided rapid improvement of symptoms and sustained
remission in a large cohort of patients across all disease severity
phenotypes.
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Spondyloarthropathies
(Including Psoriatic Arthritis)
40. EAGLE’S SYNDROME: AN UNUSUAL ASSOCIATION
WITH SERO-NEGATIVE ARTHROPATHY
Surabhi Wig1, Paul Bischoff2 and Mary Holt1
1Rheumatology, Rotherham NHS Foundation Trust, Rotherham, UK;
2Maxillofacial Surgery, Rotherham NHS Foundation Trust,
Rotherham, UK
Background: Eagle’s syndrome is characterized by recurrent throat
pain, foreign body sensations, dyphagia and facial pain as a result of
an elongated styloid process or calcified stylohyoid ligaments. It is
postulated that the stylohyoid apparatus can be a site of enthesitis in
patients with inflammatory spondlyloarthropaties, such as ankylosing
spondylitis (AS) or psoriatic arthritis. We present a patient with AS who
had symptoms attributable to enlargement and calcification of his
stylohyoid ligaments.
Methods: A 48-year-old male, diagnosed as having AS 8 years
previously, presented with generalized aches and pains and a 9-month
history of discomfort in the right jaw that he said was ‘locking and
clonking’ during eating or yawning. He also described strange
sensations in vicinity of the right side of his throat, spots in front of
his eyes, light headedness and a feeling of being slightly drunk. On
examination, he was unable to open the jaw comfortably >1 cm
anteriorly and any further movement produced a loud crepitus at the
right temporomandibular joint. Temoporomandibular joint dysfunction
was excluded.
Results: The orthopantomogram and subsequent CT scan images
demonstrated bilateral elongated and calcified stylohyoid ligaments,
which were thought to explain his signs and symptoms, resulting in a
final diagnosis of Eagle’s syndrome. He has now undergone surgical
treatment in the form of tonsillectomies with bilateral removal of
12–14 mm of the calcified stylohyoid ligaments and is showing
encouraging results post surgery.
Conclusions: Persistent jaw discomfort in a patient with an underlying
spondyloarthropathy should prompt the search for enthesopathy
affecting the stylohyoid apparatus. If present, the patient may have
Eagle’s syndrome.
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